CN112391321B

CN112391321B - Bifidobacterium bifidum NX-7 and application thereof in preparation of medicines for treating ischemic diseases

Info

Publication number: CN112391321B
Application number: CN202011356472.2A
Authority: CN
Inventors: 张召; 田甜; 郑康帝; 马燕; 赵英杰; 陈涛
Original assignee: Guangdong Longsee Medical Technology Co ltd; Guangdong Yiyuan Lanxin Biotechnology Co ltd; Foshan Langxin Biotechnology Co ltd
Current assignee: Foshan Langxin Biotechnology Co ltd; Guangdong Longsee Medical Technology Co ltd; Guangdong Yiyuan Lanxin Biotechnology Co ltd
Priority date: 2020-11-26
Filing date: 2020-11-26
Publication date: 2023-04-25
Anticipated expiration: 2040-11-26
Also published as: CN112391321A

Abstract

The invention discloses bifidobacterium bifidum NX-7 and application thereof in preparation of medicines for treating ischemic diseases, and belongs to the technical field of microorganisms. The invention discloses bifidobacterium bifidum NX-7 with a preservation number of CGMCC No.20115. The Bifidobacterium bifidum NX-7 inactivated and non-inactivated fermentation supernatant and bacterial suspension can obviously promote the growth of the intestinal veins of the zebra fish in vivo, obviously repair the damage of the intestinal veins of the zebra fish induced by a vascular endothelial cell growth factor receptor inhibitor (PTK 787), and obviously promote the damage repair of the tail fins of the zebra fish, has the potential of promoting microcirculation regeneration and reconstruction, and shows the effect of being applied to the treatment of ischemic diseases in vivo. The bifidobacterium bifidum NX-7 disclosed by the invention has great potential application prospect in the aspect of treating ischemic diseases.

Description

Bifidobacterium bifidum NX-7 and application thereof in preparation of medicines for treating ischemic diseases

Technical Field

The invention relates to the technical field of microorganisms, in particular to bifidobacterium bifidum NX-7 and application thereof in preparing a medicament for treating ischemic diseases.

Background

The main treatment methods for treating ischemic cardiovascular diseases and cerebrovascular diseases clinically at present are percutaneous coronary intervention, operation bypass, drug thrombolysis and the like, and the treatment principle is mainly to reconstruct blood perfusion and rescue ischemic tissues, however, the treatments have certain limitations. The cell proliferation, angiogenesis and repair are promoted by a drug treatment or other intervention methods, and finally the tissue regeneration and microcirculation reconstruction are achieved, so that a new thought is provided for treating cardiovascular and cerebrovascular diseases. Thus, therapeutic angiogenesis has become one of the hot spots of research for treating various ischemic diseases. Local administration of single pro-angiogenic factors (VECF, bFGF) is effective in promoting vascular growth in ischemic myocardium in animal experimental studies, but has a short half-life in vivo and high cost, and may have some potential serious toxic side effects, which undoubtedly brings many concerns and anxiety to people. Therefore, finding a treatment mode with reliable curative effect and small toxic and side effects becomes a main research direction.

Probiotics are defined as viable microorganisms that improve the balance of intestinal flora and may benefit a variety of aspects of the host physiological response, including the immune system. In addition, probiotics have been extensively studied in improving diabetes, obesity and cardiovascular and cerebrovascular diseases. However, probiotics are currently less studied and used in ischemic diseases. Meanwhile, the current international probiotics patent application is concentrated on the traditional research and development of America, japanese and Russia, and China lacks functional strains with independent intellectual property rights. The probiotics strain used by domestic production enterprises depends on import for a long time, and foreign strains are not necessarily suitable for gastrointestinal tract physiological conditions of residents in China. In addition, the lack of powerful scientific research evidence of the function of probiotics seriously affects the popularization of the probiotics and products thereof. Based on the method, aiming at the function deep excavation of strain resources, the novel probiotic bacterial strain which has independent intellectual property, specific functional property and physiological property suitable for Chinese crowd is screened out, and the method is particularly important for improving the core competitiveness of Chinese probiotic production enterprises and promoting the development of Chinese probiotic products.

Therefore, the provision of bifidobacterium bifidum NX-7 and its use in the preparation of a medicament for treating ischemic diseases is a problem to be solved by the person skilled in the art.

Disclosure of Invention

In view of the above, the invention provides bifidobacterium bifidum NX-7 and application thereof in preparing medicines for treating ischemic diseases.

In order to achieve the above purpose, the present invention adopts the following technical scheme:

the bifidobacterium bifidum Bifidobacterium bifidum NX-7 has a preservation number of CGMCC No.20115, is preserved in the China general microbiological center of the culture Collection of microorganisms, called CGMCC for short, and has a preservation date of 2020, 19 days, and is classified and named as bifidobacterium bifidum Bifidobacterium bifidum.

Further, the bifidobacterium bifidum NX-7 is applied to the preparation of medicines for treating ischemic diseases.

Further, the bifidobacterium bifidum NX-7 is applied to the preparation of medicines for promoting the growth of the intestinal veins of the zebra fish.

Further, the bifidobacterium bifidum NX-7 is applied to the preparation of medicines for promoting the repair of the vein injury under the intestines of the zebra fish.

Further, the bifidobacterium bifidum NX-7 is applied to the preparation of medicines for promoting the repair of the damage of the tail fin of the zebra fish.

Further, the bifidobacterium bifidum NX-7 is a non-inactivated bacterial suspension or a non-inactivated fermentation supernatant.

Further, the bifidobacterium bifidum NX-7 is an inactivated bacterial suspension or an inactivated fermentation supernatant.

The bifidobacterium bifidum NX-7 has the effects of promoting the growth of the intestinal veins of the zebra fish, repairing the damage of PTK787 induced intestinal veins (SIVs) of the zebra fish and promoting the repair of the damage of the tail fins of the zebra fish in vivo, has the potential of enhancing the self-repair capability of vascular tissues, and has good probiotics efficacy for treating ischemic diseases.

The strain NX-7 disclosed by the invention can be used for remarkably promoting the growth of the intestinal veins of the zebra fish in vivo, remarkably repairing the damage of the intestinal veins of the zebra fish induced by PTK787 and remarkably promoting the repair of the damage of the tail fin of the zebra fish, and comprises fermentation supernatant (extracellular secretion) and bacterial suspension (thallus) of the strain NX-7 which are inactivated and not inactivated.

Compared with the prior art, the bifidobacterium bifidum NX-7 and the application thereof in preparing medicaments for treating ischemic diseases are disclosed, the bifidobacterium bifidum NX-7 is separated and screened from healthy infant feces, can remarkably promote growth of the lower intestinal veins of the zebra fish in vivo, remarkably repair damage of the lower intestinal veins of the zebra fish induced by PTK787 and remarkably promote repair of the damage of the tail fins of the zebra fish, has the potential of promoting regeneration and reconstruction of microcirculation, shows the effect of being applied to treating ischemic diseases in vivo, and provides theoretical reference and guiding basis for developing a probiotic preparation for treating ischemic diseases by using the bifidobacterium bifidum NX-7.

Drawings

In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings that are required to be used in the embodiments or the description of the prior art will be briefly described below, and it is obvious that the drawings in the following description are only embodiments of the present invention, and that other drawings can be obtained according to the provided drawings without inventive effort for a person skilled in the art.

FIG. 1 is a diagram showing the morphology of colonies formed by bifidobacterium bifidum NX-7 of the present invention;

FIG. 2 is a graph showing microscopic morphological observations of bifidobacterium bifidum NX-7 after gram staining in accordance with the present invention;

FIG. 3 is a graph showing the effect of inactivated and non-inactivated bifidobacterium bifidum NX-7 fermentation supernatants and bacterial suspensions on the development of the intestinal veins of zebra fish: a zebra fish intestinal vein budding imaging chart;

FIG. 4 is a graph showing the effect of inactivated and non-inactivated bifidobacterium bifidum NX-7 fermentation supernatants and bacterial suspensions on the development of the intestinal veins of zebra fish: quantitative analysis of the number of buds of the vein under the zebra fish intestines;

FIG. 5 is a graph showing the repair effect of the inactivated and non-inactivated fermentation supernatant and bacterial suspension of bifidobacterium bifidum NX-7 on PTK787 induced intestinal vein injury of zebra fish: fluorescence imaging images of the intestinal veins of the zebra fish;

FIG. 6 is a graph showing the repair effect of the inactivated and non-inactivated fermentation supernatant and bacterial suspension of bifidobacterium bifidum NX-7 on PTK787 induced intestinal vein injury of zebra fish: quantitative analysis of the number of veins under the intestines of zebra fish;

FIG. 7 is a graph showing the effect of inactivated and non-inactivated bifidobacterium bifidum NX-7 fermentation supernatants and bacterial suspensions on repair of zebra fish tail fin damage according to the present invention: visual pictures of zebra fish tail fin injury repair;

FIG. 8 is a graph showing the effect of inactivated and non-inactivated fermentation supernatants and bacterial suspensions of bifidobacterium bifidum NX-7 on repair of zebra fish tail fin damage: statistics of zebra fish tail fin injury repair.

Detailed Description

The following description of the embodiments of the present invention will be made clearly and completely with reference to the accompanying drawings, in which it is apparent that the embodiments described are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.

EXAMPLE 1 isolation, identification and preservation of bifidobacterium bifidum NX-7

(1) Separating: infant feces are subjected to gradient dilution and then are respectively inoculated into a TPY solid culture medium, an MRS solid culture medium, a BHI solid culture medium and a BS solid culture medium, anaerobic culture is carried out for 48 hours at 37 ℃, and single colony on a flat plate is picked for streaking separation to obtain pure colonies. Pure bacterial colony on the flat plate is inoculated into BS liquid culture medium, anaerobic culture is carried out for 12-16 h at 37 ℃, 20% glycerol is added, and the mixture is placed in a refrigerator at-80 ℃ for preservation.

(2) Identification of strain morphology: the selected strain is observed under a microscope after gram staining, and gram positive bacteria are purple and gram negative bacteria are red.

(3) Molecular biological identification of strains: genomic DNA was extracted from the obtained strain, and a full-length fragment of 16S rDNA was amplified by PCR technique using the universal primers 27F and 1492R of 16S rDNA, followed by sequencing to identify the species of the strain.

27F：5’-AGAGTTTGATCCTGGCTCAG-3’；SEQ ID NO.1；

1492R：5’-GGTTACCTTGTTACGACTT-3’；SEQ ID NO.2。

Experimental results: the strain screened from fresh feces of healthy infants in Guangzhou city of Guangdong province is identified by morphological observation and 16S rDNA, wherein the strain NX-7 is identified as bifidobacterium bifidum, and the 16S rDNA sequence is shown as SEQ ID NO. 3.

CTTACCATGCAGTCGAACGGGATCCATCGGGCTTTGCTTGGTGGTGAGAGTGGCGAACGGGTGAGTAATGCGTGACCGACCTGCCCCATGCTCCGGAATAGCTCCTGGAAACGGGTGGTAATGCCGGATGTTCCACATGATCGCATGTGATTGTGGGAAAGATTCTATCGGCGTGGGATGGGGTCGCGTCCTATCAGCTTGTTGGTGAGGTAACGGCTCACCAAGGCTTCGACGGGTAGCCGGCCTGAGAGGGCGACCGGCCACATTGGGACTGAGATACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGCAAGCCTGATGCAGCGACGCCGCGTGAGGGATGGAGGCCTTCGGGTTGTAAACCTCTTTTGTTTGGGAGCAAGCCTTCGGGTGAGTGTACCTTTCGAATAAGCGCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGCGCAAGCGTTATCCGGATTTATTGGGCGTAAAGGGCTCGTAGGCGGCTCGTCGCGTCCGGTGTGAAAGTCCATCGCTTAACGGTGGATCTGCGCCGGGTACGGGCGGGCTGGAGTGCGGTAGGGGAGACTGGAATTCCCGGTGTAACGGTGGAATGTGTAGATATCGGGAAGAACACCGATGGCGAAGGCAGGTCTCTGGGCCGTCACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGGTGGACGCTGGATGTGGGGCACGTTCCACGTGTTCCGTGTCGGAGCTAACGCGTTAAGCGTCCCGCCTGGGGAGTACGGCCGCAAGGCTAAAACTCAAAGAAATTGACGGGGGCCCGCACAAGCGGCGGAGCATGCGGATTAATTCGATGCAACGCGAAGAACCTTACCTGGGCTTGACATGTTCCCGACGACGCCAGAGATGGCGTTTCCCTTCGGGGCGGGTTCACAGGTGGTGCATGGTCGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTCGCCCCGTGTTGCCAGCACGTTATGGTGGGAACTCACGGGGGACCGCCGGGGTTAACTCGGAGGAAGGTGGGGATGACGTCAGATCATCATGCCCCTTACGTCCAGGGCTTCACGCATGCTACAATGGCCGGTACAGCGGGATGCGACATGGCGACATGGAGCGGATCCCTGAAAACCGGTCTCAGTTCGGATCGGAGCCTGCAACCCGGCTCCGTGAAGGCGGAGTCGCTAGTAATCGCGGATCAGCAACGCCGCGGTGAATGCGTTCCCGGGCCTTGTACACACCGCCCGTCAAGTCATGAAAGTGGGCAGCACCCGAAGCCGGTGGCCTAACCCCTTGTGGGATGGAGCCGTCTAAGTAGCTCA；SEQ ID NO.3。

The single colony of the strain is inoculated on a BS solid culture medium, white colonies which are good in anaerobic growth, spherical and neat in edge at 37 ℃ are shown in figure 1, and gram staining is positive in figure 2. The strain is preserved in China general microbiological culture Collection center (CGMCC), china national institute of sciences of China, including national institute of microbiology, national institute of sciences, no.3, north Chen West Lu, korea, beijing, the preservation date is 2020, the classification name is bifidobacterium bifidum Bifidobacterium bifidum, and the preservation number is CGMCC No.20115.

EXAMPLE 2 preparation of bifidobacterium bifidum NX-7 fermentation supernatant (extracellular secretion) and bacterial suspension (bacterial cells)

Inoculating Bifidobacterium bifidum NX-7 into BS liquid culture medium after activating culture, culturing at 37deg.C for 15 hr, and regulating concentration of fermentation bacteria to 1×10 ⁶ Centrifuging at 4deg.C and 6000r/min for 10min to obtain culture supernatant and thallus precipitate, filtering the supernatant with 0.22 μm filter membrane to obtain fermentation supernatant (extracellular secretion); after the bacterial cell precipitate is washed twice by PBS, the bacterial cell is resuspended by PBS, and the cell concentration is regulated to be 1 multiplied by 10 ⁶ CFU/mL to obtain bacterial suspension (thallus); the fermentation supernatant (extracellular secretion) and the bacterial suspension (bacterial cells) are heated at 121 ℃ for 15min to prepare heat-inactivated fermentation supernatant (extracellular secretion) and bacterial suspension (bacterial cells).

Example 3 Effect of Bifidobacterium bifidum NX-7 on the development of the vein under the intestine of zebra fish

Selecting healthy zebra fish Tg (fli 1: EGFP) developed to 2hpf (hours post fertilization), placing in 6-well cell culture plate, 15 pieces/well, adding PBS into blank group, adding non-inactivated or inactivated bacterial suspension into bacterial suspension group, adding non-inactivated into fermentation supernatant groupOr inactivating 3mL of fermentation supernatant, replacing the solution every 24 hours, incubating for 72 hours at 28 ℃, anaesthetizing the zebra fish by using tricaine, observing the growth condition of the vein under the intestines under a fluorescence microscope, photographing, and counting the number of budding of the vein under the intestines. SPSS19.0 software is adopted for statistical data processing, and experimental data are all adopted

The data is expressed as a one-way analysis of variance. Each experimental group was compared with the blank group: * P (P)<0.05，**P<0.01，***P<0.005。

As a result, as shown in FIGS. 3 and 4, the lower intestinal veins of the zebra fish in the blank group showed almost no sprouting (0.47.+ -. 0.17). Whereas the intestinal veins of zebra fish of the group of bifidobacterium bifidum NX-7, which is not inactivated, have budding phenomenon (shown by arrow in figure 3); meanwhile, the budding numbers of the non-inactivated bacterial suspension of bifidobacterium bifidum NX-7 and the lower intestinal veins of the zebra fish in the fermentation supernatant group are respectively 1.53+/-0.19 and 1.80+/-0.26, and the average difference is obvious (P < 0.01) compared with the blank group (0.47+/-0.17) (FIG. 4). In addition, the intestinal veins of zebra fish of the Bifidobacterium bifidum NX-7 inactivated bacterial suspension and fermentation supernatant group also have sprouting phenomenon (shown by arrow in FIG. 3); meanwhile, the budding numbers of the intestinal veins of the zebra fish in the suspension of the Bifidobacterium bifidum NX-7 inactivated bacteria and the fermentation supernatant group are respectively 1.27+/-0.15 and 1.60+/-0.29, and the average difference is obvious (P < 0.05) compared with the blank group (0.47+/-0.17) (FIG. 4). Therefore, the results show that the bacterial suspension and fermentation supernatant of the bifidobacterium bifidum NX-7 inactivated and not inactivated can obviously promote the growth of new blood vessels in vivo, have the potential of promoting microcirculation regeneration and reconstruction, and show the effect of being applied to the treatment of ischemic diseases in vivo.

EXAMPLE 4 repair of PTK 787-induced damage to the intestinal veins of zebra fish by bifidobacterium bifidum NX-7

Healthy zebra fish Tg (fli 1: EGFP) developed to 2hpf (hours post fertilization) was selected and placed in 24-well cell culture plates, 15 pieces/well, PBS was added to the blank group, 0.03. Mu.g/mL PTK787 (Sigma-Aldrich) solution was added to the model group, the bacterial suspension group and the fermentation supernatant group, and 1mL of each well was incubated at 28℃for 24 hoursAfterwards, the PTK787 solution was discarded, PBS was added to the blank and model groups, the non-inactivated or inactivated bacterial suspension was added to the bacterial suspension group, the non-inactivated or inactivated fermentation supernatant was added to the fermentation supernatant group, 1mL each well was incubated at 28℃for 48 hours, the zebra fish was anesthetized with three-caine, the growth of the lower intestinal veins was observed under a fluorescence microscope and photographed, and then the number of lower intestinal veins was counted. SPSS19.0 software is adopted for statistical data processing, and experimental data are all adopted

The data is expressed as a one-way analysis of variance. Comparison of each experimental group with model group: * P (P)<0.05，**P<0.01，***P<0.005。

As can be seen from fig. 5 and 6, the vein development under the zebra fish intestines in the blank group is good, and the blood vessels grow orderly (10.73±0.56 pieces); the complete inferior vena jejuni of the zebra fish in the model group (PTK 787) is obviously reduced (shown by an arrow) (5.93+/-0.36) and has obvious dissimilarity (P < 0.005) compared with the blank group (10.73+/-0.56) (figure 6), which shows that the current zebra fish inferior vena jejuni injury model is successfully constructed.

From FIGS. 5 and 6, it is clear that the intestinal veins of zebra fish in the group of the non-inactivated bacterial suspension and fermentation supernatant of bifidobacterium bifidum NX-7 develop well, the blood vessels grow orderly and orderly, and the intestinal veins have sprouting phenomenon (shown by arrows in FIG. 5); meanwhile, the number of the intestinal veins of the zebra fish in the fermentation supernatant group is 8.00+/-0.38 and 8.80+/-0.49 respectively, and the average difference is obvious (P < 0.01) compared with the model group (5.93+/-0.36) in the Bifidobacterium bifidum NX-7 non-inactivated bacterial suspension (figure 6). In addition, the bacterial suspension inactivated by bifidobacterium bifidum NX-7 and the lower intestinal veins of the zebra fish of the fermentation supernatant group also develop well, the blood vessels grow orderly and orderly, and the lower intestinal veins of the zebra fish of the inactivated fermentation supernatant group also have sprouting phenomenon (shown by arrows in fig. 5); meanwhile, the number of the intestinal veins of the zebra fish in the suspension and fermentation supernatant groups inactivated by bifidobacterium bifidum NX-7 is 7.67+/-0.40 and 8.00+/-0.41 respectively, and the average difference is obvious (P < 0.05) compared with the model group (5.93+/-0.36) (FIG. 6). Therefore, the results show that the bacterial suspension and fermentation supernatant of the bifidobacterium bifidum NX-7 inactivated and not inactivated can obviously promote the damage repair of blood vessels in vivo, have the potential of promoting microcirculation regeneration and reconstruction, and show the effect of being applied to the treatment of ischemic diseases in vivo.

Example 5 Effect of Bifidobacterium bifidum NX-7 on repair of injury to the tail fin of zebra fish

Zebra fish (3 dpf) of a normal wild type AB series are selected, placed in a 6-hole cell culture plate, zebra fish tail fins are cut off by a surgical knife under a stereoscopic microscope, photographed and recorded at the time of 0dpa (day post amputation), then transferred into a 96-hole cell culture plate, PBS is added into a model group, non-inactivated or inactivated bacterial suspension is added into a bacterial suspension group, non-inactivated or inactivated fermentation supernatant is added into a fermentation supernatant group, 200 mu L of each hole is added into a fermentation supernatant group, 20 pieces of each group are incubated to 3dpa, and then the zebra fish are anesthetized by three-caine and photographed and recorded under the stereoscopic microscope. Zebra fish tail fin lengths L1 and L2 were counted at 0dpa and 3dpa, respectively, using Image J software. The difference between L1 and L2 is the regenerated length of the zebra fish tail fin. SPSS19.0 software is adopted for statistical data processing, and experimental data are all adopted

As can be seen from fig. 7 and 8, the zebra fish tail fins of the model group are not grown completely, and the regrowth length of the tail fins is 63.49±2.12 μm. The non-inactivated bacterial suspension of bifidobacterium bifidum NX-7 and the zebra fish tail fins of the fermentation supernatant group are almost complete, the regrowth lengths of the tail fins are 83.06+/-3.50 mu m and 91.74+/-4.39 mu m respectively, and the difference is obvious (P < 0.005) compared with the model group (63.49+/-2.12 mu m). In addition, the zebra fish tail fins of the bifidobacterium bifidum NX-7 inactivated bacterial suspension and fermentation supernatant group are almost complete, the regrowth lengths of the tail fins are 77.42+/-2.89 μm and 85.85+/-3.64 μm respectively, and the difference is obvious (P < 0.05) compared with the model group (63.49+/-2.12 μm). Therefore, the results show that the inactivated and non-inactivated bacterial suspension and fermentation supernatant of the bifidobacterium bifidum NX-7 can promote the damage repair of the zebra fish tail fin, and have the potential of enhancing the self-repair capability of vascular tissues.

The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.

Sequence listing

<110> Guangdong south China core medical science and technology Co., ltd. Of Langshan

<120> bifidobacterium bifidum NX-7 and its use in preparing medicament for treating ischemic diseases

<160> 3

<170> SIPOSequenceListing 1.0

<210> 1

<211> 20

<212> DNA

<213> Artificial Sequence

<400> 1

agagtttgat cctggctcag 20

<210> 2

<211> 19

<212> DNA

<213> Artificial Sequence

<400> 2

ggttaccttg ttacgactt 19

<210> 3

<211> 1415

<212> DNA

<213> Artificial Sequence

<400> 3

cttaccatgc agtcgaacgg gatccatcgg gctttgcttg gtggtgagag tggcgaacgg 60

gtgagtaatg cgtgaccgac ctgccccatg ctccggaata gctcctggaa acgggtggta 120

atgccggatg ttccacatga tcgcatgtga ttgtgggaaa gattctatcg gcgtgggatg 180

gggtcgcgtc ctatcagctt gttggtgagg taacggctca ccaaggcttc gacgggtagc 240

cggcctgaga gggcgaccgg ccacattggg actgagatac ggcccagact cctacgggag 300

gcagcagtgg ggaatattgc acaatgggcg caagcctgat gcagcgacgc cgcgtgaggg 360

atggaggcct tcgggttgta aacctctttt gtttgggagc aagccttcgg gtgagtgtac 420

ctttcgaata agcgccggct aactacgtgc cagcagccgc ggtaatacgt agggcgcaag 480

cgttatccgg atttattggg cgtaaagggc tcgtaggcgg ctcgtcgcgt ccggtgtgaa 540

agtccatcgc ttaacggtgg atctgcgccg ggtacgggcg ggctggagtg cggtagggga 600

gactggaatt cccggtgtaa cggtggaatg tgtagatatc gggaagaaca ccgatggcga 660

aggcaggtct ctgggccgtc actgacgctg aggagcgaaa gcgtggggag cgaacaggat 720

tagataccct ggtagtccac gccgtaaacg gtggacgctg gatgtggggc acgttccacg 780

tgttccgtgt cggagctaac gcgttaagcg tcccgcctgg ggagtacggc cgcaaggcta 840

aaactcaaag aaattgacgg gggcccgcac aagcggcgga gcatgcggat taattcgatg 900

caacgcgaag aaccttacct gggcttgaca tgttcccgac gacgccagag atggcgtttc 960

ccttcggggc gggttcacag gtggtgcatg gtcgtcgtca gctcgtgtcg tgagatgttg 1020

ggttaagtcc cgcaacgagc gcaaccctcg ccccgtgttg ccagcacgtt atggtgggaa 1080

ctcacggggg accgccgggg ttaactcgga ggaaggtggg gatgacgtca gatcatcatg 1140

ccccttacgt ccagggcttc acgcatgcta caatggccgg tacagcggga tgcgacatgg 1200

cgacatggag cggatccctg aaaaccggtc tcagttcgga tcggagcctg caacccggct 1260

ccgtgaaggc ggagtcgcta gtaatcgcgg atcagcaacg ccgcggtgaa tgcgttcccg 1320

ggccttgtac acaccgcccg tcaagtcatg aaagtgggca gcacccgaag ccggtggcct 1380

aaccccttgt gggatggagc cgtctaagta gctca 1415

Claims

1. Bifidobacterium bifidumBifidobacterium bifidumNX-7 is characterized in that the preservation number is CGMCC No.20115.

2. Use of bifidobacterium bifidum NX-7 as claimed in claim 1 in the manufacture of a medicament for promoting growth of the vein of zebra fish intestinal cells.

3. Use of bifidobacterium bifidum NX-7 as claimed in claim 1 in the manufacture of a medicament for promoting repair of vein lesions in the intestinal tract of zebra fish.

4. Use of bifidobacterium bifidum NX-7 as claimed in claim 1 for the preparation of a medicament for promoting repair of zebra fish tail fin damage.

5. The use according to any one of claims 2-4, wherein said bifidobacterium bifidum NX-7 is a non-inactivated bacterial suspension or a non-inactivated fermentation supernatant.

6. The use according to any one of claims 2-4, wherein said bifidobacterium bifidum NX-7 is an inactivated bacterial suspension or an inactivated fermentation supernatant.